Molecular Diagnostics Market Growth, Size, Trends Analysis - By Product, By Test Location, By Technology, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Molecular Diagnostics Market Introduction and Overview

According to SPER market research, 'Global Molecular Diagnostics Market Size- By Product, By Test Location, By Technology, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Molecular Diagnostics Market is predicted to reach 39.08 billion by 2034 with a CAGR of 4.26%.

Molecular diagnostics is the identification of genetic variants with the aim of simplifying diagnosis, prognosis, subclassification, and monitoring of therapeutic response. It is a group of techniques for using molecular biology in medical diagnostics that look at biological markers in the proteome and genome as well as the way that genes are expressed by cells as proteins. In order to identify biologic markers in a genome and proteome, molecular diagnostics are widely used, powerful.

The high cost of molecular diagnostic technologies is a significant barrier to their market expansion. This equipment is usually only accessible to small labs, clinics, and practitioners with limited funds due to their expensive cost. The need for a large financial investment, particularly for smaller enterprises, restricts the purchase of these devices. This cost barrier prevents molecular diagnostic technology from being widely used in many healthcare settings.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Test Location, By Technology, By Application.

Regions covered

North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Companies Covered

Abbott, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., BIOMARIEUX, Danaher, F. Hoffmann-La Roche, Ltd., Grifols, Hologic Inc. (Gen Probe), Illumina, Inc., QIAGEN, Siemens Healthineers AG, Sysmex Corporation, Others.

Molecular Diagnostics Market Segmentation:

By Product: Based on the Product, Global Molecular Diagnostics Market is segmented as; Instruments, Regards, Others.

By Test Location: Based on the Test Location, Global Molecular Diagnostics Market is segmented as; Point of care, Self-test or OTC, Central laboratories.

By Technology: Based on the Technology, Global Molecular Diagnostics Market is segmented as; Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-Generation Sequencing, In Situ Hybridization, DNA Microarrays, Other.

By Test-type: Based on the Test-type, Global Molecular Diagnostics Market is segmented as; Lateral Flow Immunoassay, Nucleic Acid Lateral Flow Assay.

By Application: Based on the Application, Global Molecular Diagnostics Market is segmented as; Oncology, Pharmacogenomics, Infectious disease, Genetic Testing, Neurological disease, Cardiovascular disease, Microbiology, Others.

Product Code: HLCA2508

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Molecular Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Molecular Diagnostics Market

7. Global Molecular Diagnostics Market, By Product (USD Million) 2021-2034

7.1. Instruments
7.2. Regards
7.3. Others

8. Global Molecular Diagnostics Market, By Test Location (USD Million) 2021-2034

8.1. Point of care
8.2. Self-test or OTC
8.3. Central laboratories

9. Global Molecular Diagnostics Market, By Technology (USD Million) 2021-2034

9.1. Polymerase Chain Reaction
9.2. Isothermal Nucleic Acid Amplification Technology
9.3. DNA Sequencing & Next-Generation Sequencing
9.4. In Situ Hybridization
9.5. DNA Microarrays
9.6. Other

10. Global Molecular Diagnostics Market, By Application (USD Million) 2021-2034

10.1. Oncology
- 10.1.1. Breast Cancer
- 10.1.2. Prostate Cancer
- 10.1.3. Colorectal Cancer
- 10.1.4. Cervical
- 10.1.5. Kidney
- 10.1.6. Liver
- 10.1.7. Blood
- 10.1.8. Lung
- 10.1.9. Other
10.2. Pharmacogenomics
10.3. Infectious disease
- 10.3.1. MRSA
- 10.3.2. Clostridium difficile
- 10.3.3. Vancomycin-resistant enterococci
- 10.3.4. Carbapenem-resistant bacteria testing
- 10.3.5. Flu
- 10.3.6. Respiratory syncytial virus (RSV)
- 10.3.7. Candida
- 10.3.8. Tuberculosis and drug-resistant TB
- 10.3.9. Meningitis
- 10.3.10. Gastro-intestinal panel testing
- 10.3.11. Chlamydia
- 10.3.12. Gonorrhea
- 10.3.13. HIV
- 10.3.14. Hepatitis C
- 10.3.15. Hepatitis B
- 10.3.16. Other Infectious Diseases
10.4. Genetic Testing
- 10.4.1. Newborn screening
- 10.4.2. Predictive and presymptomatic testing
- 10.4.3. Others
10.5. Neurological disease
10.6. Cardiovascular disease
10.7. Microbiology
10.8. Others

11. Global Molecular Diagnostics Market (USD Million) 2021-2034

11.1. Global Molecular Diagnostics Market Size and Market Share

12. Global Molecular Diagnostics Market, By Region (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Abbott
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Agilent Technologies, Inc.
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. BD
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Bio-Rad Laboratories, Inc.
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. BIOMARIEUX
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Danaher
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. F. Hoffmann-La Roche, Ltd.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Grifols
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Hologic Inc. (Gen Probe)
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Illumina, Inc.
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. QIAGEN
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
13.12. Siemens Healthineers AG
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
13.13. Sysmex Corporation
- 13.13.1. Company details
- 13.13.2. Financial outlook
- 13.13.3. Product summary
- 13.13.4. Recent developments
13.14. Others